

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Form 3 Holdings Reported.

Form 4 Transactions Reported.

**ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0362
Estimated average burden hours per response:	1.0

1. Name and Address of Reporting Person* <u>KAZIMI A J</u> _____ (Last) (First) (Middle) 2525 WEST END AVE. SUITE 950 _____ (Street) NASHVILLE TN 37203 _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>CUMBERLAND PHARMACEUTICALS INC [ CPIX ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p style="text-align: center;"><b>Chairman and CEO</b></p>
	3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
				Amount	(A) or (D)	Price			
Common Stock	11/12/2020		L4	15 <sup>(1)(2)</sup>	A	\$3.03	5,792,672	D	
Common Stock	11/13/2020		L4	15 <sup>(1)</sup>	A	\$3.04	5,792,687	D	
Common Stock	11/16/2020		L4	15 <sup>(1)</sup>	A	\$3.05	5,792,702	D	
Common Stock	11/17/2020		L4	15 <sup>(1)</sup>	A	\$2.96	5,792,717	D	
Common Stock	11/18/2020		L4	15 <sup>(1)</sup>	A	\$3.01	5,792,732	D	
Common Stock	11/19/2020		L4	15 <sup>(1)</sup>	A	\$2.98	5,792,747	D	
Common Stock	11/20/2020		L4	15 <sup>(1)</sup>	A	\$3.02	5,792,762	D	
Common Stock	11/23/2020		L4	15 <sup>(1)</sup>	A	\$3.03	5,792,777	D	
Common Stock	11/24/2020		L4	15 <sup>(1)</sup>	A	\$3.03	5,792,792	D	
Common Stock	11/25/2020		L4	15 <sup>(1)</sup>	A	\$3.01	5,792,807	D	
Common Stock	11/27/2020		L4	15 <sup>(1)</sup>	A	\$2.99	5,792,822	D	
Common Stock	11/30/2020		L4	15 <sup>(1)</sup>	A	\$3.05	5,792,837	D	
Common Stock	12/01/2020		L4	15 <sup>(1)</sup>	A	\$3.01	5,792,852	D	
Common Stock	12/02/2020		L4	15 <sup>(1)</sup>	A	\$3.03	5,792,867	D	
Common Stock	12/03/2020		L4	15 <sup>(1)</sup>	A	\$3.02	5,792,882	D	
Common Stock	12/04/2020		L4	15 <sup>(1)</sup>	A	\$3.02	5,792,897	D	
Common Stock	12/07/2020		L4	15 <sup>(1)</sup>	A	\$3.01	5,792,912	D	
Common Stock	12/08/2020		L4	15 <sup>(1)</sup>	A	\$3.05	5,792,927	D	
Common Stock	12/09/2020		L4	15 <sup>(1)</sup>	A	\$3.03	5,792,942	D	
Common Stock	12/10/2020		L4	15 <sup>(1)</sup>	A	\$3.05	5,792,957	D	
Common Stock	12/11/2020		L4	15 <sup>(1)</sup>	A	\$3.04	5,792,972	D	
Common Stock	12/14/2020		L4	15 <sup>(1)</sup>	A	\$3.04	5,792,987	D	
Common Stock	12/15/2020		L4	15 <sup>(1)</sup>	A	\$3.03	5,793,002	D	
Common Stock	12/16/2020		L4	15 <sup>(1)</sup>	A	\$3.03	5,793,017	D	
Common Stock	12/17/2020		L4	15 <sup>(1)</sup>	A	\$3.13	5,793,032	D	
Common Stock	12/18/2020		L4	15 <sup>(1)</sup>	A	\$3.17	5,793,047	D	
Common Stock	12/21/2020		L4	15 <sup>(1)</sup>	A	\$3.15	5,793,062	D	
Common Stock	12/22/2020		L4	7 <sup>(1)</sup>	A	\$3.13	5,793,069	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date					

**Explanation of Responses:**

- The purchase reported in this Form 5 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020.
- Filing 6 of 6.

**Remarks:**

A.J. Kazimi by /s/ Michael Bonner as attorney-in-fact      02/05/2021

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**